Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Raphael N. Alolga

Raphael N. Alolga

China Pharmaceutical University, China

Title: A Sino-African Pharmacokinetic comparison of berberine: the contribution of the intestinal microbiota

Biography

Biography: Raphael N. Alolga

Abstract

Berberine is one of the world’s most widely used natural products. It has gained recognition as a drug in many Asian and African countries, and also as a dietary supplement in many other countries. However, pharmacokinetic (PK) comparisons of berberine in different racial/ethnic groups are lacking. Our study compared the PK differences of berberine in 20 healthy male Africans and Chinese and investigated the possible underlying mechanisms for the racial differences. The plasma levels of berberine after oral administration were monitored for 12 hours by liquid chromatography with mass spectrometry. The Cmax and AUC in the Africans were 2.67- and 2.0-fold higher than the Chinese respectively. Microbiotal compositions by 16S rRNA pyrosequencing showed higher abundance of the genera Prevotella, Bacteroides, and Megamonas (34.22, 13.88, and 10.68%, respectively) in the Chinese than the Africans (30.08, 9.43, and 0.48%, respectively). Scatter plot showed a strong negative correlation between the microbiotal abundance and the berberine AUC, especially for the genus Prevotella (r = -0.813) and its species.  To confirm the effects of microbiota on the PK of berberine, we compared the metabolic capacities of microbiota between the two races. A more extensive metabolism was observed in Chinese with 1.83-fold higher metabolites, possibly contributing to the lower AUC than the Africans. In conclusion, significant PK differences were observed between Africans and Chinese, which is partly attributable to variations in gut microbiota and its corresponding metabolic capacity. Our findings are of clinical significance in the design of individualized dosage regimen based on differential microbiotal compositions.